• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

更新后的国际 IgA 肾病预测工具在活检后一至两年的儿童中的应用。

Application of the updated International IgA Nephropathy Prediction Tool in children one or two years post-biopsy.

机构信息

Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada; BC Renal, Vancouver, British Columbia, Canada.

Fondazione Ricerca Molinette, Regina Margherita Hospital, Turin, Italy.

出版信息

Kidney Int. 2024 Nov;106(5):913-927. doi: 10.1016/j.kint.2024.07.012. Epub 2024 Jul 31.

DOI:10.1016/j.kint.2024.07.012
PMID:39094695
Abstract

The pediatric International IgA Nephropathy (IgAN) Prediction Tool comprises two models with and without ethnicity and is the first method to predict the risk of a 30% decline in estimated glomerular filtration rate (eGFR) or kidney failure in children at the time of biopsy using clinical risk factors and Oxford MEST histology scores. However, it is unknown if the Prediction Tool can be applied after a period of observation post-biopsy. Using an international multi-ethnic cohort of 947 children with IgAN, 38% of whom were followed into adulthood, the Prediction Tool was updated for use one year after biopsy. Compared to the original pediatric Prediction Tool, the updated post-biopsy Prediction Tool had a better model fit with higher R (51%/50% vs 20%), significant increase in 4-year C-statistics (0.83 vs 0.73/0.69, ΔC 0.09 [95% confidence interval 0.07-0.10] and ΔC 0.14 [0.12-0.15]) and better 4-year calibration with lower integrated calibration indices (0.74/0.54 vs 2.45/1.01). Results were similar after internal validation and when the models were applied two years after biopsy. Trajectories of eGFR after a baseline one year post-biopsy were non-linear and those at higher predicted risk started with a lower eGFR and experienced a more rapid decline over time. In children, eGFR had a variable rate of increase until 15-18 years old and then decreased linearly with a more rapid decline in higher risk groups that was similar to young adults of comparable risk. Thus, the original pediatric Prediction Tool should be used in children at the time of biopsy, and the updated pediatric Prediction Tool should be used to re-evaluate risk one or two years after biopsy.

摘要

儿科国际 IgA 肾病 (IgAN) 预测工具包含有和无种族两个模型,是第一种在活检时使用临床危险因素和牛津 MEST 组织学评分预测 IgAN 患儿 30%肾小球滤过率 (eGFR) 下降或肾功能衰竭风险的方法。然而,尚不清楚该预测工具是否可以在活检后进行一段时间的观察后应用。本研究使用国际多民族队列的 947 名 IgAN 患儿,其中 38%的患儿随访至成年期,更新了活检后 1 年的预测工具。与原始儿科预测工具相比,更新后的活检后预测工具具有更好的模型拟合度,R 值更高 (51%/50% vs 20%),4 年 C 统计量显著增加 (0.83 vs 0.73/0.69,ΔC 0.09[95%置信区间 0.07-0.10]和 ΔC 0.14[0.12-0.15]),4 年校准更好,综合校准指数更低 (0.74/0.54 vs 2.45/1.01)。内部验证和在活检后两年应用模型时,结果相似。活检后 1 年基础期后 eGFR 的轨迹是非线性的,那些预测风险较高的患儿 eGFR 起点较低,随着时间的推移,下降速度更快。在儿童中,eGFR 的增长率是可变的,直到 15-18 岁,然后随着风险较高组的 eGFR 下降速度加快而呈线性下降,与风险相当的年轻成年人相似。因此,在活检时应使用原始儿科预测工具,在活检后 1-2 年应使用更新的儿科预测工具重新评估风险。

相似文献

1
Application of the updated International IgA Nephropathy Prediction Tool in children one or two years post-biopsy.更新后的国际 IgA 肾病预测工具在活检后一至两年的儿童中的应用。
Kidney Int. 2024 Nov;106(5):913-927. doi: 10.1016/j.kint.2024.07.012. Epub 2024 Jul 31.
2
Updating the International IgA Nephropathy Prediction Tool for use in children.更新国际 IgA 肾病预测工具,以用于儿童。
Kidney Int. 2021 Jun;99(6):1439-1450. doi: 10.1016/j.kint.2020.10.033. Epub 2020 Nov 18.
3
Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy.应用国际 IgA 肾病预测工具于活检后一至两年。
Kidney Int. 2022 Jul;102(1):160-172. doi: 10.1016/j.kint.2022.02.042. Epub 2022 Apr 29.
4
External Validation of the International IgA Nephropathy Prediction Tool.国际 IgA 肾病预测工具的外部验证。
Clin J Am Soc Nephrol. 2020 Aug 7;15(8):1112-1120. doi: 10.2215/CJN.16021219. Epub 2020 Jul 2.
5
The MEST score provides earlier risk prediction in lgA nephropathy.MEST 评分可更早预测 IgA 肾病的风险。
Kidney Int. 2016 Jan;89(1):167-75. doi: 10.1038/ki.2015.322.
6
Evaluating a New International Risk-Prediction Tool in IgA Nephropathy.评估 IgA 肾病的新型国际风险预测工具。
JAMA Intern Med. 2019 Jul 1;179(7):942-952. doi: 10.1001/jamainternmed.2019.0600.
7
Delta corticomedullary apparent diffusion coefficient on MRI as a biomarker for prognosis in IgA nephropathy.MRI上的皮质髓质Delta表观扩散系数作为IgA肾病预后的生物标志物
Ren Fail. 2025 Dec;47(1):2441394. doi: 10.1080/0886022X.2024.2441394. Epub 2024 Dec 17.
8
Is it possible to predict the evolution of IgAN? Validation of the IgA nephropathy progression calculator and its relationship with MEST-C score in our population.能否预测IgA肾病的进展?IgA肾病进展计算器的验证及其在我们研究人群中与MEST-C评分的关系。
Nefrologia (Engl Ed). 2019 Sep-Oct;39(5):523-530. doi: 10.1016/j.nefro.2018.10.015. Epub 2019 Mar 20.
9
Urinary Matrix Metalloproteinase 7 and Prediction of IgA Nephropathy Progression.尿基质金属蛋白酶 7与 IgA 肾病进展的预测。
Am J Kidney Dis. 2020 Mar;75(3):384-393. doi: 10.1053/j.ajkd.2019.07.018. Epub 2019 Oct 9.
10
External validation of the pediatric International IgA Nephropathy Prediction Tool in a central China cohort.中国中部队列中儿科国际 IgA 肾病预测工具的外部验证。
Clin Exp Nephrol. 2024 Jan;28(1):59-66. doi: 10.1007/s10157-023-02402-5. Epub 2023 Sep 15.

引用本文的文献

1
Causal relationship between gastroesophageal reflux disease and IgA nephropathy: a Mendelian randomization analysis.胃食管反流病与IgA肾病之间的因果关系:一项孟德尔随机化分析
Ren Fail. 2025 Dec;47(1):2526690. doi: 10.1080/0886022X.2025.2526690. Epub 2025 Jul 23.
2
Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts.使用国际IgA肾病预测工具来富集临床试验队列。
Kidney Int Rep. 2025 Jan 20;10(4):1283-1287. doi: 10.1016/j.ekir.2025.01.025. eCollection 2025 Apr.